Repros Therapeutics Inc (RPRX)

[exwannabe]

Sounds just like Tony Snow interviewing Bush.

How about some real questions?

Why 15 patients in the palceboe arms of the 4 trials, especially when you know many will drop out?

Why no SPA?

The FDA does not like companies to use higher dosages than have been shown effective. For anemmia, why is the 15mg dose not in the P3?

What are the endpoints? In particular the company states the trials are 2.5X bigger than the P2s. So, this implies a composite endpoint of both arms treatment arms, or a P reduction. If composite, isn't that a danger in the fibr. trial? If a P reduction, what?


I know all these issues were beaten to death, so no need to ask. Just present the softballs.